by McKesson Ventures | Jun 4, 2019 | Portfolio News
GRAIL, a healthcare company focused on the early detection of cancer, today announced new data from its Circulating Cell-free Genome Atlas (CCGA) study that demonstrates the ability of GRAIL’s technology to detect cancer early with a single blood test. The data...
by McKesson Ventures | May 13, 2019 | Portfolio News
Liquid biopsy company GRAIL announced today that its multi-cancer test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration. This investigational blood test is in development for the early detection of multiple cancer types in...
by McKesson Ventures | Sep 27, 2018 | Portfolio News
Trident Medical Center of Charleston, South Carolina, announced that it and Sarah Cannon, the Cancer Institute of HCA Healthcare, will participate in a study called STRIVE, which focuses on developing a test for early cancer detection. The STRIVE study is designed to...
by McKesson Ventures | Aug 10, 2018 | Portfolio News
GRAIL Inc. recently announced the appointment of Hal Barron, M.D., and Hans Bishop to its Board of Directors. Hal Barron is globally recognized for his clinical and scientific leadership. Currently he is the Chief Scientific Officer and President of R&D at...
by McKesson Ventures | Jul 12, 2018 | Portfolio News
GRAIL, a company whose mission is to detect cancer early, when it can be cured, recently announced the appointment of several key leaders as it continues to build its executive team. George Golumbeski has been appointed as President and will also serve on GRAIL’s...
